Drugs / VV1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04291105 | Apr 2020 → Oct 2026 expected | colorectal cancer, head and neck squamous cell carcinoma, melanoma | Vyriad, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01042379 | Mar 2010 → Dec 2030 expected | HER2 positive breast carcinoma, angiosarcoma, female breast carcinoma, hormone receptor-positive breast cancer +1 | QuantumLeap Healthcare Collaborative | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VV1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04291105 ↗ |
| Route | Other | “VV1, 3x10\^9 TCID50 once (day-8), Intra-tumoral injection” NCT01042379 ↗ |